• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Professional Introduction to 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one (CAS No. 31435-75-3)

6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one, a compound with the chemical identifier CAS No. 31435-75-3, is a heterocyclic organic molecule that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of dihydronaphthalenone derivatives, which are known for their diverse biological activities and potential therapeutic applications. The presence of a dimethylamino group in its structure contributes to its unique chemical properties, making it a subject of interest for further exploration in drug discovery and development.

The molecular structure of 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one consists of a naphthalene core with hydroxyl and amino substituents, which are crucial for its reactivity and interaction with biological targets. This structural motif has been widely studied for its ability to modulate various biological pathways, including enzyme inhibition and receptor binding. The compound's versatility makes it a valuable scaffold for designing novel pharmacophores that could lead to the development of new therapeutic agents.

In recent years, there has been a growing interest in exploring the pharmacological potential of dihydronaphthalenone derivatives. Research has demonstrated that these compounds can exhibit a range of biological activities, such as anti-inflammatory, antioxidant, and anticancer properties. Specifically, studies have shown that derivatives of this class can interact with key enzymes and receptors involved in disease pathways, making them promising candidates for further investigation.

One of the most compelling aspects of 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one is its ability to serve as a precursor for more complex molecules. Chemists have leveraged this compound to synthesize novel derivatives with enhanced biological activity and improved pharmacokinetic profiles. For instance, modifications to the dimethylamino group or the naphthalene core have led to compounds with increased potency and selectivity against specific targets. These findings highlight the compound's potential as a building block in medicinal chemistry.

The synthesis of 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one involves multi-step organic reactions that require precise control over reaction conditions. The process typically begins with the functionalization of a naphthalene derivative followed by the introduction of the dimethylamino group. Advanced synthetic techniques, such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions, are often employed to achieve high yields and purity. These synthetic strategies underscore the compound's importance in both academic research and industrial applications.

Recent advancements in computational chemistry have also contributed to our understanding of 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one's behavior. Molecular modeling studies have provided insights into how this compound interacts with biological targets at the atomic level. These simulations have helped researchers predict potential drug candidates and optimize their structures for better efficacy. The integration of computational methods with experimental approaches has accelerated the drug discovery process significantly.

The pharmacological evaluation of 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one has revealed several interesting findings. In vitro studies have shown that this compound can inhibit key enzymes involved in inflammatory pathways, such as COX-2 and LOX. Additionally, it has demonstrated antioxidant properties by scavenging reactive oxygen species (ROS) and protecting cells from oxidative damage. These effects make it a promising candidate for treating chronic inflammatory diseases and neurodegenerative disorders.

Preclinical studies have further explored the therapeutic potential of this compound. Animal models have shown that 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one can reduce inflammation and pain without significant side effects. These results support its further development as a lead compound for novel therapeutics. However, additional research is needed to fully understand its mechanism of action and long-term safety profile.

The future directions for research on 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one are multifaceted. Scientists are exploring ways to enhance its bioavailability and metabolic stability through structural modifications. Additionally, combination therapies involving this compound with other drugs are being investigated to improve treatment outcomes. The growing body of evidence supporting its potential makes it an exciting area for future pharmaceutical development.

In conclusion, 6-(Dimethylamino)-3,4-dihydronaphthalen-1(2H)-one (CAS No. 31435-75-3) is a versatile heterocyclic compound with significant pharmacological potential. Its unique structure and biological activities make it a valuable scaffold for drug discovery and development. As research continues to uncover new applications for this molecule, it is poised to play an important role in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)